Cognition Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for age-related degenerative disorders of the central nervous system and retina. Its lead candidate, CT1812, is being investigated for Alzheimer's disease, dementia with Lewy bodies, and dry age-related macular degeneration (dry AMD). CT1812 is an orally delivered modulator that crosses the blood-brain and blood-retina barriers, selectively binding to the sigma-2 receptor (S2R) complex. This modulation restores normal synapse function and critical cellular processes like autophagy, cholesterol biosynthesis, and vesicle trafficking. We show 13 historical shares outstanding datapoints in our coverage of CGTX's shares outstanding history.
Understanding the changing numbers of CGTX shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like CGTX versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching CGTX by allowing them to research CGTX shares outstanding history
as well as any other stock in our coverage universe. |
Free CGTX Email Alerts:
Video: Shares Outstanding Importance
